Scientist Solutions: International Life Science Community By Scientists For Scientists

Thanks to our sponsors who make this site possible

    

Scientist-Solutions

 



Google+

At Scientist Solutions we cherish our role as a trusted source of information for scientists.  We hope that our newly designed site will make it easier than ever for you to access everything we have to offer.   Things may have moved around a little, but rest assured that all the features you enjoyed on our old site (the forums, the protocols, the events, my bench space, blogs)  are still here.  

Our Discussion Forums

Scientist Solutions began as a discussion board for life scientists and that is still one of our core offerings.   If you are looking for the discussion forums, please click "The Forums"  from the navigation bar above or click here.

Protocols and SciEvents

Always on the look out for new ways to help scientists to help each other,  Scientist Solutions introduced a new protocols section and an events section to our site in the past year.   Both have been very popular.   If you haven't yet discovered these listings, we invite you to do so now. 

Our Protocol Finder provides an easily searchable database of protocols that you can use both to find a protocol you need or to share the protocols that you rely on.  Just click "Protocol Finder" from the navigation bar above, or click here.

Our SciEvents section is setting out to be the most comprehensive listing of conferences, seminars, classes and webinars for life scientists on the web.   Search events listings by date, topic or type of event.    You are most welcome to add your own events to our listing too.   Just click SciEvents from the navigation bar above, or click here.

My Bench SpaceMembership Management

Are you looking for how to log in or wondering what happened to your bench space?     On our new site, we have made it much easier for you to manage your account and profile.   After logging in (note that the log in area has moved down the page),  you will see your new member status panel on the right hand side of the home page and every page.    Look here for an overview of your member information and find easy access to your newly remodeled My Bench Space, where you'll be able to edit your account information and preferences and manage your public profile.   Just click "Go to My Bench Space" from your member status panel or click here.

Blogging

Notice that featured blogs are now presented on the home page just below this article.   To read all blogs, just click the "view more" link below the featured blogs.   To create your own blog, go to your My Bench Space pages and click on the "blogs" tab.  To get to My Bench Space, log in then click the "Go to My Bench Space" link in your member status panel (see above) or just click here

Give us your feedback

We understand that it takes a little adjustment time to get used to a new design.  We apologize for any temporary confusion, but hope that once you've familiarized yourself with the new design and features you will be very pleased.   Either way, we would love to hear what you think.  Please share your opinion by clicking the 'contact us'  link at the top right of any page and send us a note or click here.




Latest Member Blogs

Member
Total Posts: 1
6/14/2017
09:29PM
Member
Total Posts: 1
6/14/2017
02:18PM
Member
Total Posts: 1
6/13/2017
09:49AM




Science News Feeds

Click a source to select it and see feeds below

BioScience News
Pharmaceutical News
Biotechnology News
Today's Science News
This Week in Science
Science (Editorial)
Science Now
Nextwave
New York Times
BBC
Bioscreening
Journals
Journal of Biology
Nature
European Journal of Cell Biology
Virology Journal
Science
PNAS
Magazines
New Scientist
The Scientist
Pharmaceutical Business Review
Life Sciences World
Science News

Biotechnology - Google News
Google News
Galapagos NV (GLPG) Price Target Lowered to $121.00 at Nomura - Sports Perspectives

Galapagos NV (GLPG) Price Target Lowered to $121.00 at Nomura
Sports Perspectives
Galapagos NV logo Galapagos NV (NASDAQ:GLPG) had its price objective reduced by analysts at Nomura from $108.00 to $121.00 in a report issued on Thursday, June 22nd. The firm presently has a “buy” rating on the biotechnology company's stock.

and more »
Weiss Multi Strategy Advisers LLC Holds Position in Advaxis, Inc. (NASDAQ:ADXS) - The Cerbat Gem

Weiss Multi Strategy Advisers LLC Holds Position in Advaxis, Inc. (NASDAQ:ADXS)
The Cerbat Gem
American International Group Inc. now owns 20,666 shares of the biotechnology company's stock valued at $169,000 after buying an additional 1,459 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Advaxis by 4.8 ...

and more »
Heron Therapeutics, Inc. (HRTX) Upgraded by ValuEngine to “Sell” - Sports Perspectives

Heron Therapeutics, Inc. (HRTX) Upgraded by ValuEngine to “Sell”
Sports Perspectives
The biotechnology company reported ($1.00) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.06. The firm had revenue of $3.63 million during the quarter, compared to the consensus estimate of $1.96 million.

and more »
Weiss Multi Strategy Advisers LLC Has $318000 Position in uniQure NV (NASDAQ:QURE) - Transcript Daily

Weiss Multi Strategy Advisers LLC Has $318000 Position in uniQure NV (NASDAQ:QURE)
Transcript Daily
The institutional investor owned 55,000 shares of the biotechnology company's stock after buying an additional 40,000 shares during the period. Weiss Multi Strategy Advisers LLC owned about 0.22% of uniQure N.V. worth $318,000 at the end of the most ...

and more »
iShares Nasdaq Biotechnology (NASDAQ:IBB) Moves Up 2.68% For The Week - The Herald

iShares Nasdaq Biotechnology (NASDAQ:IBB) Moves Up 2.68% For The Week
The Herald
iShares Nasdaq Biotechnology (NASDAQ:IBB) performed nicely this week, continuing its impressive near-term upward movement. The stock has moved north 2.68% over the past week of trading. Looking further out, over the past twelve months, iShares ...

and more »
Weiss Multi Strategy Advisers LLC Takes Position in Puma Biotechnology Inc (NYSE:PBYI) - Chaffey Breeze

Weiss Multi Strategy Advisers LLC Takes Position in Puma Biotechnology Inc (NYSE:PBYI)
Chaffey Breeze
Puma Biotechnology logo Weiss Multi Strategy Advisers LLC purchased a new stake in Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional ...

and more »
Meiji Yasuda Life Insurance Co Raises Position in Biogen Inc. (NASDAQ:BIIB) - Sports Perspectives

Meiji Yasuda Life Insurance Co Raises Position in Biogen Inc. (NASDAQ:BIIB)
Sports Perspectives
Biogen logo Meiji Yasuda Life Insurance Co increased its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 3.7% during the first quarter, according to its most recent filing with the SEC. The fund owned 5,566 shares of the biotechnology company's stock ...

and more »
Skandinaviska Enskilda Banken AB publ Buys New Stake in Opko Health, Inc. (OPK) - BNB Daily (blog)

Skandinaviska Enskilda Banken AB publ Buys New Stake in Opko Health, Inc. (OPK)
BNB Daily (blog)
The fund purchased 556,300 shares of the biotechnology company's stock, valued at approximately $4,450,000. Skandinaviska Enskilda Banken AB publ owned approximately 0.10% of Opko Health as of its most recent SEC filing. A number of other ...

and more »
Tower Research Capital LLC TRC Acquires Shares of 1870 Galapagos NV (NASDAQ:GLPG) - BNB Daily (blog)

Tower Research Capital LLC TRC Acquires Shares of 1870 Galapagos NV (NASDAQ:GLPG)
BNB Daily (blog)
The fund purchased 1,870 shares of the biotechnology company's stock, valued at approximately $161,000. A number of other institutional investors have also recently modified their holdings of the stock. Renaissance Technologies LLC increased its stake ...

and more »
Cowen and Company Reaffirms Buy Rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - BNB Daily (blog)

Cowen and Company Reaffirms Buy Rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BNB Daily (blog)
The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.33. BioMarin Pharmaceutical had a negative net margin of 48.43% and a negative return on equity of ...

and more »